









市場行情
/
股票
/
nasdaq-vnda
/

Vanda Pharmaceuticals Inc

VNDA

6.840USD

-0.190-2.70%

收盤 12/23, 16:00（美東）報價延遲15分鐘

404.21M總市值

虧損本益比TTM



Vanda Pharmaceuticals Inc

6.840

-0.190-2.70%

概覽公司財務分析

概覽

公司

財務

分析

關於 Vanda Pharmaceuticals Inc 公司

Vanda Pharmaceuticals Inc. is a global biopharmaceutical company focused on the development and commercialization of therapies to address unmet medical needs and improve the lives of patients. The Company’s commercial portfolio consist of three products: Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and for the treatment of nighttime sleep disturbances in Smith-Magenis syndrome (SMS) and PONVORY for the treatment of relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. In addition, it has a number of drugs and/or additional indications for current products in development, including Bysanti, Tradipitant, Imsidolimab, VTR-297, VQW-765, and others. Bysanti is the active metabolite of Fanapt.

Vanda Pharmaceuticals Inc簡介



公司代碼VNDA

公司名稱Vanda Pharmaceuticals Inc

上市日期Apr 12, 2006

CEOPolymeropoulos (Mihael Hristos)

員工數量368

證券類型Ordinary Share

年結日Apr 12

公司地址Suite 300E

城市WASHINGTON

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United States of America

郵編20037

電話12027343400

網址https://www.vandapharma.com/

公司代碼VNDA

上市日期Apr 12, 2006

CEOPolymeropoulos (Mihael Hristos)

Vanda Pharmaceuticals Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Dr. Mihael Hristos Polymeropoulos, M.D.

Chairman of the Board, President, Chief Executive Officer

2.34M

+0.43%

Mr. Gunther Birznieks

Senior Vice President - Business Development

411.63K

+73.26%

Mr. Kevin Patrick Moran

Chief Financial Officer, Senior Vice President, Treasurer

329.46K

+118.08%

Mr. Richard W. Dugan

Lead Independent Director

177.45K

+50.09%

Dr. Tage Honore, Ph.D.

Independent Director

123.47K

+92.19%

Ms. Anne Sempowski Ward

Independent Director

119.07K

+98.97%

Dr. Stephen Ray Mitchell, M.D.

Independent Director

97.08K

+116.43%

Mr. Timothy I. Williams

Senior Vice President, General Counsel, Secretary

Ms. Phaedra S. Chrousos

Independent Director

Mr. Joakim (Kim) Wijkstrom

Senior Vice President, Chief Marketing Officer

名稱

名稱/職務

職務

持股

持股變動

Dr. Mihael Hristos Polymeropoulos, M.D.

Chairman of the Board, President, Chief Executive Officer

2.34M

+0.43%

Mr. Gunther Birznieks

Senior Vice President - Business Development

411.63K

+73.26%

Mr. Kevin Patrick Moran

Chief Financial Officer, Senior Vice President, Treasurer

329.46K

+118.08%

Mr. Richard W. Dugan

Lead Independent Director

177.45K

+50.09%

Dr. Tage Honore, Ph.D.

Independent Director

123.47K

+92.19%

Ms. Anne Sempowski Ward

Independent Director

119.07K

+98.97%

收入明細

單位: USD更新時間: 10月6日週一

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

業務USD

名稱

營收

佔比

Fanapt

29.29M

55.70%

Hetlioz

16.19M

30.79%

PONVORY

7.10M

13.51%

由於公司未披露，未能獲取相關數據

業務

地區

業務USD

名稱

營收

佔比

Fanapt

29.29M

55.70%

Hetlioz

16.19M

30.79%

PONVORY

7.10M

13.51%

股東統計

更新時間: 11月16日週日

持股股東

股東類型

持股股東

佔比

BlackRock Institutional Trust Company, N.A.

9.77%

The Vanguard Group, Inc.

6.02%

Renaissance Technologies LLC

5.88%

Millennium Management LLC

5.50%

Dimensional Fund Advisors, L.P.

4.34%

其他

68.49%

持股股東

佔比

BlackRock Institutional Trust Company, N.A.

9.77%

The Vanguard Group, Inc.

6.02%

Renaissance Technologies LLC

5.88%

Millennium Management LLC

5.50%

Dimensional Fund Advisors, L.P.

4.34%

其他

68.49%

股東類型

持股股東

佔比

Investment Advisor

28.53%

Investment Advisor/Hedge Fund

27.12%

Hedge Fund

20.23%

Individual Investor

7.19%

Research Firm

1.71%

Pension Fund

0.27%

Bank and Trust

0.20%

Sovereign Wealth Fund

0.19%

Family Office

0.09%

其他

14.45%

機構持股



更新時間: 10月1日週三

報告期間

機構數

持股數

持股佔比

持股變動

2025Q3

373

46.45M

78.60%

-9.99M

2025Q2

417

50.75M

85.90%

-11.31M

2025Q1

426

48.51M

82.37%

-12.27M

2024Q4

444

46.48M

79.71%

-15.23M

2024Q3

446

47.42M

81.36%

-14.93M

2024Q2

445

46.99M

80.73%

-18.42M

2024Q1

434

53.50M

92.97%

-11.41M

2023Q4

445

55.38M

96.27%

-9.21M

2023Q3

446

56.79M

98.75%

-12.15M

2023Q2

434

60.42M

105.19%

-10.16M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

BlackRock Institutional Trust Company, N.A.

5.99M

10.13%

-31.47K

-0.52%

Jun 30, 2025

The Vanguard Group, Inc.

3.54M

5.99%

+46.84K

+1.34%

Jun 30, 2025

Renaissance Technologies LLC

3.45M

5.83%

-118.97K

-3.34%

Jun 30, 2025

Millennium Management LLC

3.12M

5.28%

+980.75K

+45.84%

Jun 30, 2025

Dimensional Fund Advisors, L.P.

2.59M

4.38%

+46.08K

+1.81%

Jun 30, 2025

Tang Capital Management, LLC

2.35M

3.98%

Jun 30, 2025

Polymeropoulos (Mihael Hristos)

2.34M

3.95%

+10.00K

+0.43%

Aug 07, 2025

BlackRock Financial Management, Inc.

2.43M

4.12%

+286.64K

+13.35%

Jun 30, 2025

Acadian Asset Management LLC

1.73M

2.93%

-155.16K

-8.22%

Jun 30, 2025

Two Sigma Investments, LP

1.34M

2.26%

+925.23K

+225.21%

Jun 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

iShares Neuroscience and Healthcare ETF

0.49%

Invesco NASDAQ Future Gen 200 ETF

0.49%

SPDR SSGA US Small Cap Low Volatility Index ETF

0.12%

ALPS Medical Breakthroughs ETF

0.1%

Federated Hermes MDT Small Cap Core ETF

0.09%

iShares Micro-Cap ETF

0.05%

ProShares Ultra Nasdaq Biotechnology

0.04%

Franklin US Small Cap Multifactor Index ETF

0.04%

Goldman Sachs ActiveBeta US Small Cap Equity ETF

0.04%

JPMorgan Diversified Return U.S. Small Cap Equity ETF

0.03%

iShares Neuroscience and Healthcare ETF

佔比0.49%

Invesco NASDAQ Future Gen 200 ETF

佔比0.49%

SPDR SSGA US Small Cap Low Volatility Index ETF

佔比0.12%

ALPS Medical Breakthroughs ETF

佔比0.1%

Federated Hermes MDT Small Cap Core ETF

佔比0.09%

iShares Micro-Cap ETF

佔比0.05%

ProShares Ultra Nasdaq Biotechnology

佔比0.04%

Franklin US Small Cap Multifactor Index ETF

佔比0.04%

Goldman Sachs ActiveBeta US Small Cap Equity ETF

佔比0.04%

JPMorgan Diversified Return U.S. Small Cap Equity ETF

佔比0.03%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

常見問題

Vanda Pharmaceuticals Inc的前五大股東是誰？



Vanda Pharmaceuticals Inc的前五大股東如下：
BlackRock Institutional Trust Company, N.A.
持有股份：5.99M
佔總股份比例：10.13%。
The Vanguard Group, Inc.
持有股份：3.54M
佔總股份比例：5.99%。
Renaissance Technologies LLC
持有股份：3.45M
佔總股份比例：5.83%。
Millennium Management LLC
持有股份：3.12M
佔總股份比例：5.28%。
Dimensional Fund Advisors, L.P.
持有股份：2.59M
佔總股份比例：4.38%。